Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,069 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib.
Tripathi A, Supko JG, Gray KP, Melnick ZJ, Regan MM, Taplin ME, Choudhury AD, Pomerantz MM, Bellmunt J, Yu C, Sun Z, Srinivas S, Kantoff PW, Sweeney CJ, Harshman LC. Tripathi A, et al. Clin Cancer Res. 2020 Dec 1;26(23):6122-6131. doi: 10.1158/1078-0432.CCR-20-2306. Epub 2020 Sep 17. Clin Cancer Res. 2020. PMID: 32943461 Free PMC article. Clinical Trial.
Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer.
Harshman LC, Tripathi A, Kaag M, Efstathiou JA, Apolo AB, Hoffman-Censits JH, Stadler WM, Yu EY, Bochner BH, Skinner EC, Downs T, Kiltie AE, Bajorin DF, Guru K, Shipley WU, Steinberg GD, Hahn NM, Sridhar SS. Harshman LC, et al. Among authors: tripathi a. Clin Genitourin Cancer. 2018 Jun;16(3):213-218. doi: 10.1016/j.clgc.2017.11.004. Epub 2017 Dec 6. Clin Genitourin Cancer. 2018. PMID: 29289519 Free PMC article.
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC. Martínez Chanzá N, et al. Among authors: tripathi a. Lancet Oncol. 2019 Apr;20(4):581-590. doi: 10.1016/S1470-2045(18)30907-0. Epub 2019 Feb 28. Lancet Oncol. 2019. PMID: 30827746 Free PMC article.
PARP inhibitors in castration-resistant prostate cancer.
Tripathi A, Balakrishna P, Agarwal N. Tripathi A, et al. Cancer Treat Res Commun. 2020;24:100199. doi: 10.1016/j.ctarc.2020.100199. Epub 2020 Jul 22. Cancer Treat Res Commun. 2020. PMID: 32745972 Free article.
Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
Hussain A, Tripathi A, Pieczonka C, Cope D, McNatty A, Logothetis C, Guise T. Hussain A, et al. Among authors: tripathi a. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):290-300. doi: 10.1038/s41391-020-00296-y. Epub 2020 Oct 7. Prostate Cancer Prostatic Dis. 2021. PMID: 33028943 Free PMC article. Review.
2,069 results